CVTX - CV Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext

To: scaram(o)uche who wrote (410)	6/25/2009 3:08:56 PM
From: scaram(o)uche	of 411

Bioorg Med Chem Lett. 2009 Jun 1;19(11):3063-6. Epub 2009 Apr 8. Aryl sulfonamido tetralin inhibitors of the Kv1.5 ion channel.Gross MF, Castle NA, Zou A, Wickenden AD, Yu W, Spear KL. Icagen Inc, NC 27709, United States. Aryl sulfonamido tetralins based on lead compound 2a were synthesized and evaluated for Kv1.5 inhibitory activity. Several compounds having IC(50) values less then 0.1 microM were identified. Kv1.5 inhibitors have the potential to be atrium-selective agents for the treatment of atrial fibrillation.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 PreviousNext